Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Department Of Defense was posted on May 5, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

BUPROPION HYDROCHLO

Closed
SPE2DP-26-T-3269Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412
New
Federal
6505--Dutasteride CapsulesThe Department of Veterans Affairs National Acquisition Center plans to issue a Request for Proposal (RFP 36E79726R0029) for the procurement of Dutasteride Capsules to serve multiple federal agencies, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted contract aims to secure a reliable supply source for Dutasteride 0.5MG capsules in both 30-count and 90-count bottles, with annual estimated usage of approximately 3,912 and 25,502 bottles respectively. The contract will be awarded to a single responsible offeror who can provide an uninterrupted supply and will have a one-year base period followed by four one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must supply the drug under the exact name on the label, with a unique National Drug Code (NDC) exclusive to the offeror. The contractor’s label must be the sole label on the product, with VA labels designed to adhere securely on top without obscuring important information such as barcodes, expiration dates, and lot numbers. Packaging requirements include safety caps that meet specific design criteria with a minimum bottle volume of 120cc and cylindrical shape to accommodate appropriate labeling sizes. The solicitation will be released in a commercial item format in accordance with FAR Part 12 around June 22, 2026, with proposals due by July 7, 2026. Interested parties should monitor SAM.gov for updates and submit offers electronically; efforts to obtain paper copies will not be accommodated. The contract specialist and primary point of contact for this procurement is Richard Mahario.
Nac Pharmaceuticals (36E797)

POSTED

1 day ago

DEADLINE

in 21 days

AI Contract Overview

Show more

This contract concerns the procurement of Bupropion Hydrochloride sustained release tablets, specifically in 150 mg dosage units packaged in bottles of 60 tablets each. The contract mandates strict adherence to packaging and labeling requirements in accordance with Medical Marking Standard No. 1A, including clear labeling with NSN, manufacturer and CAGE codes, manufacture date, expiration or retest date, and contract or lot numbers. The product must be stored at controlled room temperatures between 59°F and 86°F, kept dry and out of light to maintain quality. Packaging is required to be commercial grade, ensuring protection from damage during shipping and handling, and must comply with Department of Defense fuel and shipping standards for acceptance and safe delivery to the specified destination. The contract is regulated under FDA guidelines and incorporates multiple technical and quality requirements as detailed in the Defense Logistics Agency's master list, with the version current at solicitation or award date governing compliance. The item is classified as a Type I (Code Q) product with a non-extendable shelf life of 36 months. It explicitly prohibits the intentional inclusion of mercury or mercury-containing compounds in any supplied hardware or materials unless exceptions apply. The contract sets delivery terms at 20 days to the destination point, with inspection and acceptance occurring upon delivery. The contracting agency is the Department of Defense’s Medical Supply Chain Pharmacy FSA, with the place of performance designated as Fort Stewart, and includes clear points of contact for procurement follow-up.

General Info

Procurement of 150mg Bupropion tablets, strict labeling, packaging, 36-month shelf life, 20-day delivery.

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

NAICS

325412 - Pharmaceutical Preparation Manufacturing View NAICS

Place of Performance

BLDG 1509 WEST 6TH STREET, FORT STEWART, GA, 31314-5185, US

Set-Aside

NONE

Documents

(1)

SPE2DP-26-T-3269.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Office AddressUS

Full Description

Show more
BUPROPION HYDROCHLO
BUPROPION HCL SUSTAINED RELEASE TABLETS
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
150 MG., 60'S. UNIT OF ISSUE BOTTLE .. LABELING AND MARKING MUST IN
ACCORDANCE WITH MEDICAL MARKING STANDARD NO. 1A DATED 4 FEBRUARY 2013.
1 BT = 60 TT
LABELS SHALL INCLUDE: NSN MANUFACTURER AND CAGE DATE OF MANUFACTURE,
EXPIRATION OR RETEST DATE CONTRACT NUMBER/LOT NUMBER. STORE AT ROOM
TEMPERATURE BETWEEN 59OF AND 86OF (15OCTO 30OC). KEEP DRY AND OUT OF
LIGHT.
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description.
APPLICABLE TO ALL MEDICAL ACQUISITIONS:
PACKAGING AND PACKING SHALL BE COMMERCIAL AS SPECIFIED IN THE PROCUREMENT DOCUMENT.
EACH COMPLETE UNIT SHALL BE PROPERLY PACKAGED IN A SUITABLE SEALED UNIT CONTAINER CAPABLE OF PROTECTING THE CONTENTS FROM DAMAGE AND/OR BREAKAGE.
UNITS SHALL BE PACKED IN SUITABLE COMMERCIAL EXTERIOR (SHIPPING) CONTAINERS (EXPORT WHEN NECESSARY) WHICH SHALL INSURE ACCEPTANCE AND SAFE DELIVERY BY COMMON OR OTHER CARRIER, AT THE LOWEST RATE, TO POINT OF DELIVERY CALLED FOR IN THE CONTRACT OR ORDER.
MATERIAL MUST BE MARKED IAW MEDICAL MARKING STANDARD NO. 1. THIS SUPERCEDES ALL REFERENCES TO MIL-STD-129.
COPIES OF MEDICAL MARKING STANDARD NO. 1 (MMS NO. 1) MAY BE OBTAINED BY CONTACTING DLA TROOP SUPPORT VIA EMAIL TO fssb@dla.mil. MMS NO. 1 IS ALSO AVAILABLE ONLINE AT: https://www.dla.mil/Logistics-Operations/Packaging/
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
SPE2DP-26-T-3269
SECTION B
MERCURY OR MERCURY CONTAINING COMPOUNDS SHALL
NOT BE INTENTIONALLY ADDED TO<(>,<)> OR COME IN DIRECT
CONTACT WITH<(>,<)> ANY HARDWARE OR SUPPLIES FURNISHED
UNDER THIS CONTRACT. EXCEPTION: FUNCTIONAL MERCURY
USED IN BATTERIES, FLUORESCENT LIGHTS, REQUIRED
INSTRUMENTS; SENSORS OR CONTROLS; WEAPON SYSTEMS;
AND CHEMICAL ANALYSIS REAGENTS SPECIFIED BY NAVSEA.
PORTABLE FLUORESCENT LAMPS AND PORTABLE INSTRUMENTS
CONTAINING MERCURY SHALL BE SHOCK PROOF AND CONTAIN
A SECOND BOUNDARY OF CONTAINMENT OF THE MERCURY OR
MERCURY COMPOUND. (IAW NAVSEA 5100-003D).
NSN 6505014983167 1/28/16
RS020: Shelf-life requirement RS001 for a TYPE I (CODE Q) item with a shelf life of 36 months (non-extendable) applies to this item.
GLAXO WELLCOME INC DBA 34006 P/N NDC00173-0135-55 AMERISOURCEBERGEN DRUG CORP 1XUY5 P/N NDC00173-0135-55 CARDINAL HEALTH, INC. 00E55 P/N NDC00185-0415-60 AMERISOURCEBERGEN DRUG CORP 1XUY5 P/N NDC00185-0415-60 AMERISOURCEBERGEN DRUG CORP 1XUY5 P/N NDC00591-3541-60 SCIEGEN PHARMACEUTICALS INC 8NLP1 P/N NDC50228-0175-60 RADHA PHARMACEUTICALS INC 8PNH3 P/N NDC77771-0175-60
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7015009365 0001 BT 1.000
NSN/MATERIAL:6505014983167
DELIVERY (IN DAYS):0020
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
SPECIAL NSN/Part Number: 6505-01-498-3167 Quantity: 1 BT Purchase Request: 7015009365QTY: 1 Delivery: 20 days ADO